



Supplemental Figure 1. Illustration of antipsychotic discontinuation phase



Supplemental Figure 2. Flow of patients included in the analysis



Supplemental Table 1. Clinico-demographics of patients receiving antipsychotic polypharmacy (N=121)

Age, years, mean (SD)	38.8 (10.8)
Male, n (%)	78 (64.5)
Race, n (%)	
White	72 (59.5)
Black or African American	18 (14.9)
Asian	28 (23.1)
Other	3 (2.5)
Geographic region, n (%)	
North America	49 (40.5)
South America	2 (1.7)
Europe	42 (34.7)
Asia	28 (23.1)
Age at initial onset of schizophrenia, years, mean (SD)	24.9 (7.6)
Duration of schizophrenia from initial onset to pre-antipsychotic discontinuation visit, years, mean (SD)	13.4 (10.9)
Duration of schizophrenia from onset of current episode to pre-antipsychotic discontinuation visit , days, mean (SD)	19.9 (12.6)
Number of prior hospitalizations for schizophrenia	
0	18 (14.9)
1	10 (8.3)
2	11 (9.1)
3	18 (14.9)
>=4	64 (52.9)
Total defined daily dose of prior antipsychotics, mean (SD)	1.91 (1.17)
Duration of antipsychotic discontinuation, days, mean (SD)	5.4 (1.6)
Strategy of antipsychotic discontinuation	
Abrupt	58 (47.9)
Gradual	63 (52.1)
Use of concomitant psychotropic medications**, n (%)	
Pre-antipsychotic discontinuation visit	78 (64.5)
Post-antipsychotic discontinuation visit	62 (51.2)

*Except for quetiapine extended release, ** Except for Antipsychotics

Supplemental Table 2. Symptom and illness severity at pre- and post-antipsychotic discontinuation visits in patients receiving antipsychotic polypharmacy (N=121)

	Score at pre-antipsychotic discontinuation visit	Score at post-antipsychotic discontinuation visit	Change in scores between pre- and post-antipsychotic discontinuation visits	
	Mean (SD)	Mean (SD)	Mean (SD)	p-value
PANSS				
Total	93.1 (8.4)	94.5 (8.5)	1.4 (4.6)	0.001
Consensus 5-factor				
Positive	15.5 (2.4)	15.8 (2.6)	0.2 (1.4)	0.051
Negative	18.1 (3.6)	18.4 (3.8)	0.3 (1.8)	0.086
Disorganized/concrete	10.5 (2.2)	10.8 (2.1)	0.3 (1.0)	0.004
Excited	10.1 (3.0)	10.2 (3.2)	0.2 (1.5)	0.232
Depressed	7.9 (2.5)	7.7 (2.5)	-0.1 (1.3)	0.262
CGI-S	4.9 (0.5)	4.9 (0.6)	0.0 (0.3)	0.250

Supplemental Table 3 . Frequency of change in symptom and illness severity between pre- and post-antipsychotic discontinuation visits in patients receiving antipsychotic polypharmacy (N=121)

	n (%)
PANSS total score change	
<= -30%	0
> -30%, <= -20%	0
> -20%, <= -10%	3 (2.5)
> -10%, <= +10%	106 (87.6)
> +10%, <= +20%	7 (5.8)
> +20%, <= +30%	4 (3.3)
> +30%	1 (0.8)
CGI-S score change	
-2	0
-1	4 (3.3)
0	109 (90.1)
+1	8 (6.6)
+2	0